New agents for patients with estrogen receptor (ER)-positive metastatic breast cancer are being approved and examined, giving patients more ...
219
0Like
When it comes to being deaf in a hearing world, a recipe for success is to simply have “chutzpah,” and the same can be said for...
279
0Like
It has been an "embarrassment of riches" in the treatment paradigm for patients with non–small cell lung cancer (NSCLC)...
155
0Like
Treatment with Rintega (rindopepimut) plus temozolomide failed to improve overall survival (OS) compared with temozolomide and a control for...
254
0Like
Patients with advanced renal cell carcinoma (RCC) now have more second-line treatment options. In fact, the FDA recently approved Opdivo (ni...
169
0Like
Research into immunotherapy for non–small cell lung cancer (NSCLC) is progressing rapidly according to Naiyer Rizvi, and is unlikely t...
194
0Like
For years, brain cancer has been difficult to treat. After letdowns in prior research, immunotherapeutics and novel targeted therapy are pro...
184
0Like
The combination of Opdivo (nivolumab) and radiation therapy may provide better disease control and a boost in overall survival (OS) in patie...
181
0Like
Robert Ferris has been trying for years to harness the immune system to fight cancer.
“Since I got my MD/PhD 25 years ago in immunolo...
142
0Like
An affinity enhanced T-cell therapy has received an FDA breakthrough therapy designation for the treatment of patients with inoperable or me...
132
0Like